Corporate Overview/History

Corporate Overview

Company Name Solasia Pharma K.K.
Address 4F SUMITOMO FUDOSAN SHIBA-KOEN TOWER,
2-11-1 Shiba-koen, Minato-ku, Tokyo 105-0011 Japan
Phone Number +81 3 5843 8045
Date of Establishment December 2006
President & CEO Yoshihiro Arai
Scope of Business Development, marketing, import/export of pharmaceutical products and medical devices, etc.
Access Direction By Train
JR “Hamamatsucho Station” Kanasugibashi Exit, 7 minutes walk
Toei Subway Mita Line “Shiba-koen Station” A3 Exit, 2 minutes walk

Subsidiary Company (Wholly Owned)

Company Name 苏爱康医药信息咨询(上海)有限公司
Solasia Medical Information Consulting (Shanghai) Co. Ltd.
Website
[ Main Office/Shanghai Office ]
Address 上海市浦东新区世纪大道1196号世纪汇办公楼二座25层07单元
Unit07, 25F, II, Century Link Tower, No. 1196 Century Avenue, PuDong New District, Shanghai, China 200120
Phone Number +86-21-5028-1230
[ Beijing Office ]
Address 北京市朝阳区朝阳门外大街甲六号万通中心D座3层
3Floor, Tower D, Vantone Center, No.6 Chaoyangmenwai Street, Chaoyang District ,Beijing, China 100022
Phone Number +86-10-5907-0428
[ Guangzhou Office ]
Address 广州越秀区中山三路33号中华国际中心A塔14层
14/F, Tower A, China International Centre, No. 33 Zhongshan San Road, Yuexiu District, Guangzhou, China 510055
Phone Number +86-20-8114-8420

History/Timeline

Sep 2020 Launched episil® (SP-03) in South Korea
Aug 2020 License Agreement with Isofol Medical AB for exclusive license of arfolitixorin (SP-05) in Japan
Jan 2020 License Agreement with Synex for commercialization of episil® (SP-03) in South Korea
Dec 2019 License Agreement with Maruho Co., Ltd. for commercialization of PledOx® (SP-04) in Japan
Oct 2019 Obtained Commercial Approval of episil® (SP-03) in South Korea
Jul 2019 Launched episil® (SP-03) in China
Mar 2019 Launched Sancuso® (SP-01) in China
Feb 2019 Obtained Approval of episil® (SP-03) in China as new medical device
Dec 2018 Open Guangzhou Office in China
Aug 2018 License and Distribution Agreement with HB Human BioScience SAS for exclusive license of darinaparsin (SP-02) in Latin America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala)
Aug 2018 License and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in South Korea
Jul 2018 Obtained Approval of Sancuso® (SP-01) in China
Nov 2017 License Agreement with PledPharma AB (currently Egetis Therapeutics AB) for exclusive license of PledOx® (SP-04) in Japan, China and other Asian territories
Jul 2017 Obtained Approval of episil® (SP-03) in Japan as new medical device
Mar 2017 Solasia listed it’s shares on Tokyo Stock Exchange, Mothers
Feb 2017 License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of episil® (SP-03) in China excluding Beijing, Shanghai, Guangzhou and Taiwan
Nov 2016 License and Collaboration Agreement with Meiji Seika Pharma for episil® (SP-03) in Japan
Nov 2015 License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of Sancuso® (SP-01) in China excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau and Taiwan
Mar 2015 Licensed and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in Japan and China
Jan 2015 License Agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of darinaparsin (SP-02) in Japan
Dec 2014 Establishment of the subsidiary in Shanghai
Jul 2014 License Agreement with ZIOPHARM Oncology Inc. for global license and collaboration for darinaparsin (SP-02)
Jan 2013 Open Shanghai Office in China
Dec 2011 Open Beijing Representative Office in China
Mar 2011 License Agreement with ZIOPHARM Oncology Inc. for exclusive rights to darinaparsin (SP-02) in Japan, China, and other Asian territories
Feb 2010 License Agreement with Kyowa Hakko Kirin Co., Ltd. (currently Kyowa Kirin) for the sublicense of Sancuso® (SP-01) in Taiwan, Hong Kong, Singapore & Malaysia
Sep 2008 Company name changed to Solasia Pharma K.K.
May 2008 License Agreement with ProStrakan (currently Kyowa Kirin Services Limited) for exclusive rights to Sancuso® (SP-01) in Japan, China, and other Asian territories
Dec 2006 Business started as JapanBridge in the United States with investments by MPM Capital, US and ITOCHU Corporation, JP
PAGE TOP